P
AUPH icon

Pitcairn’s Aurinia Pharmaceuticals AUPH Stock Holding History

Pitcairn’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,205
Closed -$193K – 573
2022
Q2 		$193K Buy
19,205
+800
+4% +$8.94K 0.02% 561
2022
Q1 		$228K Sell
18,405
-2,848
-13% -$44K 0.02% 565
2021
Q4 		$486K Sell
21,253
-742
-3% -$17.6K 0.03% 380
2021
Q3 		$487K Sell
21,995
-9,508
-30% -$151K 0.03% 354
2021
Q2 		$408K Buy
31,503
+7,676
+32% +$97.8K 0.03% 411
2021
Q1 		$309K Buy
+23,827
New +$346K 0.02% 488

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pitcairn's AUPH Position: Q3 2022 in Review

Pitcairn sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 19,205 shares — an estimated $193K sold.

Pitcairn first reported a position in AUPH in Q1 2021 and held it in 6 quarters. The position peaked at $487K in Q3 2021. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

  • Pitcairn reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Pitcairn sold 19,205 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $193K.
  • Pitcairn first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Pitcairn's Aurinia Pharmaceuticals position peaked at $487K in Q3 2021.
  • 189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on Pitcairn's 13F filing for Q3 2022, filed 14 Nov 2022.